Amfetamine modified release - Highland Therapeutics

Drug Profile

Amfetamine modified release - Highland Therapeutics

Alternative Names: D-amphetamine sulfate capsules; Dexamfetamine modified release - Highland Therapeutics; Dextroamphetamine sulfate modified release - Highland Therapeutics; HLD 900; HLD-100

Latest Information Update: 17 Sep 2016

Price : $50

At a glance

  • Originator Highland Therapeutics
  • Developer Highland Therapeutics; Ironshore Pharmaceutical and Development
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder
  • Clinical Phase Unknown Bulimia nervosa

Most Recent Events

  • 25 Aug 2016 Phase-II clinical trials in Attention-deficit hyperactivity disorder (In children) in USA (PO) (NCT02884544)
  • 25 Aug 2016 Ironshore plans a phase IIb/III trial for ADHD in Canada
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top